No Data
No Data
Express News | Maia Biotechnology- Phase 2 Trial Thio-101 Expansion Underway; Potential Filing in 2026 for Accelerated Approval
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025
Express News | Maia Biotechnology Inc - Decreases Maximum Aggregate Offering Price to $11.2 Million - SEC Filing
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Express News | Maia Biotechnology Announces Poster Presentation at Esmo's European Lung Cancer Congress 2025